AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
With its 700,000 customers, Alan could be considered as a mature company. But the health insurance company that wants to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback